Trials / Not Yet Recruiting
Not Yet RecruitingNCT06327698
Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure
Efficacy and Safety of Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure: A Single-arm, Open-label, Multicenter Phase II Clinical Study
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hunan Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter, single-arm Phase II clinical study to evaluate the effectiveness of cadonilimab (AK104) in combination with anlotinib in the treatment of locally advanced or metastatic melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab | Injectable solution |
| DRUG | anlotinib | capsule |
Timeline
- Start date
- 2024-05-15
- Primary completion
- 2026-05-31
- Completion
- 2027-05-31
- First posted
- 2024-03-25
- Last updated
- 2024-03-25
Source: ClinicalTrials.gov record NCT06327698. Inclusion in this directory is not an endorsement.